.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Queensland Health
US Department of Justice
UBS
Dow
Express Scripts
Harvard Business School
Cipla
Novartis
Daiichi Sankyo

Generated: July 22, 2017

DrugPatentWatch Database Preview

VIEKIRA PAK (COPACKAGED) Drug Profile

« Back to Dashboard

What is the patent landscape for Viekira Pak (copackaged), and what generic Viekira Pak (copackaged) alternatives are available?

Viekira Pak (copackaged) is a drug marketed by Abbvie Inc and is included in one NDA. There are eighteen patents protecting this drug.

This drug has four hundred and sixty-eight patent family members in fifty-one countries.

The generic ingredient in VIEKIRA PAK (COPACKAGED) is dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir. One supplier is listed for this compound. Additional details are available on the dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir profile page.

Summary for Tradename: VIEKIRA PAK (COPACKAGED)

Patents:18
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list9
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VIEKIRA PAK (COPACKAGED) at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes8,691,938► SubscribeYY ► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes9,139,536► Subscribe ► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes8,686,026► SubscribeY ► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes8,268,349► SubscribeY ► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes9,006,387► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VIEKIRA PAK (COPACKAGED)

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 20146,037,157► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 20146,703,403► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: VIEKIRA PAK (COPACKAGED)

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,023,8782-iminobiotin formulations and uses thereof► Subscribe
8,853,176Methods for treating HCV► Subscribe
9,586,978Anti-viral compounds► Subscribe
8,674,112Polymorph of a pharmaceutical► Subscribe
8,809,265Methods for treating HCV► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VIEKIRA PAK (COPACKAGED)

Country Document Number Estimated Expiration
Portugal107665► Subscribe
Taiwan201519891► Subscribe
South Korea20100031092► Subscribe
Dominican RepublicP2014000067► Subscribe
Peru10832014► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VIEKIRA PAK (COPACKAGED)

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015011Lithuania► SubscribePRODUCT NAME: PARITAPREVIRUM; REGISTRATION NO/DATE: EU/1/14.982 20150115
2015011,C2340029Lithuania► SubscribePRODUCT NAME: PARITAPREVIRAS; REGISTRATION NO/DATE: EU/1/14.982 20150115
15/011Ireland► SubscribePRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REGISTRATION NO/DATE: EU/1/14/982 20150115
0730Netherlands► SubscribePRODUCT NAME: PARITAPREVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER DAARVAN; REGISTRATION NO/DATE: EU/1/14/982 20150119
/2015Austria► SubscribePRODUCT NAME: DASABUVIR ODER EIN SALZ DAVON, EINSCHLIESSLICH DASABUVIR-NATRIUM-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/14/983 20150115
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Harvard Business School
Cipla
Chinese Patent Office
Fuji
Queensland Health
Citi
Farmers Insurance
US Army
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot